(19)
(11) EP 2 419 143 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
27.06.2018 Bulletin 2018/26

(45) Mention of the grant of the patent:
09.05.2018 Bulletin 2018/19

(21) Application number: 09788995.0

(22) Date of filing: 24.07.2009
(51) International Patent Classification (IPC): 
A61K 48/00(2006.01)
A61K 47/42(2017.01)
A61P 17/00(2006.01)
A61K 39/12(2006.01)
C07K 14/005(2006.01)
C12N 15/11(2006.01)
C12N 7/04(2006.01)
A61P 35/00(2006.01)
A61K 39/00(2006.01)
C07K 16/08(2006.01)
C12N 7/00(2006.01)
C12N 15/88(2006.01)
(86) International application number:
PCT/US2009/004299
(87) International publication number:
WO 2010/120266 (21.10.2010 Gazette 2010/42)

(54)

HPV PARTICLES AND USES THEREOF

HPV-TEILCHEN UND IHRE VERWENDUNGEN

PARTICULES HPV ET UTILISATIONS ASSOCIÉES


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 13.04.2009 US 168914 P

(43) Date of publication of application:
22.02.2012 Bulletin 2012/08

(60) Divisional application:
18171291.0

(73) Proprietors:
  • INSERM - Institut National de la Santé et de la Recherche Médicale
    75013 Paris (FR)
  • Aura Biosciences, Inc.
    MA, 02140 (US)

(72) Inventors:
  • COURSAGET, Pierre L.
    75013 Paris (FR)
  • TOUZE, Antoine, A.
    F-37200 Tours (FR)
  • FLEURY, Maxime, J. J.
    F-37200 Tours (FR)
  • COMBELAS, Nicolas
    F-37200 Tours (FR)
  • DE LOS PINOS, Elisabet
    Brookline MA 02446 (US)

(74) Representative: Kirkham, Nicholas Andrew et al
Graham Watt & Co. LLP St. Botolph's House 7-9 St. Botolph's Road
Sevenoaks, Kent TN13 3AJ
Sevenoaks, Kent TN13 3AJ (GB)


(56) References cited: : 
WO-A1-99/15630
US-A1- 2005 118 191
US-A1- 2004 146 531
US-B1- 6 599 739
   
  • BOUSARGHIN L ET AL: "Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs" MOLECULAR CANCER THERAPEUTICS, vol. 8, no. 2, 27 January 2009 (2009-01-27), pages 357-365, XP002599616 ISSN: 1535-7163
  • COMBITA ALBA LUCIA ET AL: "Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate" FEMS MICROBIOLOGY LETTERS, vol. 204, no. 1, 16 October 2001 (2001-10-16), pages 183-188, XP002599856 ISSN: 0378-1097
  • BERGSDORF C ET AL: "Highly efficient transport of carboxyfluorescein diacetate succinimidyl ester into COS7 cells using human papillomavirus-like particles" FEBS LETTERS, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/S0014-5793(03)00039-5, vol. 536, no. 1-3, 11 February 2003 (2003-02-11), pages 120-124, XP004630022 ISSN: 0014-5793
  • SADEYEN J-R ET AL: "Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope" VIROLOGY, ACADEMIC PRESS,ORLANDO, US LNKD- DOI:10.1016/S0042-6822(02)00134-4, vol. 309, no. 1, 1 January 2003 (2003-01-01), pages 32-40, XP002992695 ISSN: 0042-6822
  • RYDING J ET AL: "Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles" JOURNAL OF GENERAL VIROLOGY, vol. 88, no. Part 3, March 2007 (2007-03), pages 792-802, XP002599857 ISSN: 0022-1317 DOI: DOI:10.1099/VIR.0.82449-0
  • FLEURY MAXIME J J ET AL: "Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications." PROTEIN SCIENCE, vol. 18, no. 7, 20 May 2009 (2009-05-20), pages 1425-1438, XP002599617 ISSN: 1469-896X
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).